XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.9201
-0.0487 (-5.03%)
At close: Oct 23, 2026, 4:00 PM EDT
0.9400
+0.0199 (2.16%)
After-hours: Oct 23, 2026, 6:56 PM EDT
XORTX Therapeutics Employees
As of December 31, 2023, XORTX Therapeutics had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year. That makes XORTX Therapeutics the 43,156th largest employer in the world and 6,981st in the United States.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,246,379
Market Cap
1.67M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2023 | 3 | 0 | - | 2 | 1 |
| Dec 31, 2022 | 3 | 0 | - | 3 | 0 |
| Jan 1, 2022 | 3 | - | - | 3 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Curis | 24 |
| GeoVax Labs | 19 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| Kairos Pharma | 4 |
| Oragenics | 3 |
| Silo Pharma | 3 |
XRTX News
- 16 days ago - Xortx Therapeutics outlines anticipated clinical trial application for XRx-026 - TheFly
- 16 days ago - XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout - GlobeNewsWire
- 5 weeks ago - Xortx Therapeutics announces planned FDA IND submission for XRx-026 - TheFly
- 5 weeks ago - XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity - GlobeNewsWire
- 6 weeks ago - Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo - TheFly
- 6 weeks ago - XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ - GlobeNewsWire
- 6 weeks ago - XORTX Re-Engages Investor Relations Program - GlobeNewsWire
- 1 month ago - Xortx Therapeutics terminates investor relations, marketing agreement - TheFly